Watchlist

Watchlist
Aduro Biotech, Inc. (ADRO)
Aduro Biotech, Inc. (ADRO)
Biotech Analysis Central Pharma News: AbbVie And Roche Stellar Data, Aduro Pulls The Cord, Allergan's Bargain Bin Buy
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Abbvie and Roche Put Out Amazing Phase 3 Leukemia Data News: Recently, Abbvie ( ABBV ) and Roche ( RHHBY ) announced positive phase 3 data in pat…
3 Things In Biotech You Should Learn Today: December 13, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AbbVie spikes the ball at ASH 2017 Company: AbbVie ( ABBV ) and Roche ( RHHBY ) Therap…
3 Things In Biotech You Should Learn Today: November 5, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Ionis takes its swing in Europe Company: Ionis Pharmaceuticals ( IONS ) Therapy: Inot…
Aduro Biotech beats by $0.03, misses on revenue
Aduro Biotech (NASDAQ: ADRO ): Q3 EPS of -$0.33 beats by $0.03 . Revenue of $3.79M (flat Y/Y) misses by $2.34M . Press Release More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news,
Premarket analyst action - healthcare
Heron Therapeutics (NASDAQ: HRTX ) initiated with Outperform rating and $27 (76% upside) price target by Oppenheimer. More news on: Heron Therapeutics, Inc., Voyager Therapeutics, Syros Pharmaceuticals, Healthcare stocks news, Read more …
Aduro Biotech (ADRO) Presents At LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology - Slideshow
The following slide deck was published by Aduro Biotech in conjunction with this Read more …
Aduro Biotech (ADRO) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
The following slide deck was published by Aduro Biotech in conjunction with this Read more …
3 Things In Biotech You Should Learn Today: September 28, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Aduro bounds back into the news again with another important phase 1 trial In yesterday's e…
Your Daily Pharma Scoop: Celgene's CELMoD Potential, Allergan's Senate Troubles, Abbott Approval Surge
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Celgene, by Dr Udaya Maiya, MD, Oncologis…
3 Things In Biotech You Should Learn Today: September 27, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Axovant's very bad news catapults the company downward Axovant Sciences ( AXON ) initiated …
Early-stage study of combination of Aduro's ADU-S100 and Novartis' PDR001 underway
The first patient has been dosed in a Phase 1b clinical trial assessing the combination of Aduro Biotech's ( ADRO -0.9% ) STING pathway activator ADU-S100 and Novartis' ( NVS -0.9% ) PD-1 checkpoint inhibitor PDR001 in ~175 patients with advanced/metastatic solid tumors or lymphomas….
Aduro Biotech, Inc. (ADRO)